MLR Maelor

RNS Number:7913B
Maelor PLC
10 August 2004



               Maelor Appoints Volplex(R) Distributor for Brazil



Wrexham, UK, 10 August 2004: Maelor plc, the specialist healthcare products
company, today announced that it has appointed a partner for the distribution of
its blood plasma substitute product, Volplex, in Brazil.



Zodiac Productos Farmaceuticos is a Brazilian company with experience in
marketing blood-related products, and is an affiliate of Tecnofarma SA, a major
regional pharmaceutical company based in Buenos Aires.  Zodiac will be
responsible for the regulatory submission, marketing and sales of Volplex in
Brazil.



Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia (lower than normal
blood volume).  Since launch last year, the product has established itself by
winning major contracts in the #8m UK market through its distributor Cambridge
Laboratories. Volplex has expanded its international franchise over the last few
months, gaining regulatory approval in Argentina in December 2003 where it will
be launched later this year. In preparation for launch Maelor has established
partners in South Africa and Bangladesh (where regulatory applications have
already been submitted) and also in Australia, China and South Korea.



Stephen Appelbee, CEO of Maelor plc, said: "This is another major market for
Volplex and follows other recent distributorship deals in China and South Korea.
Brazil's pharmaceutical market is just emerging from a major restructuring, and
the economy as a whole appears to be overcoming its recent difficulties."



                                     -ends-



For further information:


Maelor plc          Stephen Appelbee, Chief Executive Officer Tel: 01978 810 153
Financial Dynamics  Ben Atwell/Lucy Briggs                    Tel: 0207 831 3113



Notes to editors:

Maelor plc



Maelor is an AiM-listed specialist healthcare products company.  Maelor operates
on a virtual basis, outsourcing both product development and manufacturing, and
outlicensing the sale of its products to distribution partners.  The company has
several products on the market including OptiFlo(R), ContiSolTM, Volplex and
Maelor Oral Syringes.



OptiFlo, a urethral catheter maintenance range, launched in the UK in June 1999
and distributed through Bard Limited, has gained a 42% share of the UK community
prescription market.



ContiSol, Maelor's own brand urethral catheter maintenance range, has already
been launched in Spain and Greece.  The product has also gained approval in
Argentina where launch is expected shortly.



Maelor Oral Syringes are individually-wrapped devices designed to give doses of
liquid medicines accurately to patients who cannot easily be treated by other
routes of administration.



Maelor has various products under development including micelle propofol, a
reformulation of the world's biggest selling general anaesthetic.



Volplex(R) and ContiSolTM are trademarks of Maelor Pharmaceuticals Limited.
OptiFlo(R) is a trademark of Bard Limited.





                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRQKCKBOBKDKFK

Maelor (LSE:MLR)
Historical Stock Chart
From Nov 2024 to Dec 2024

Maelor (LSE:MLR)
Historical Stock Chart
From Dec 2023 to Dec 2024